Nanogen Announces Collaboration with Canadian Agencies to Develop Veterinary and Bioterror Diagnostics
SAN DIEGO--(BUSINESS WIRE)--Nanogen, Inc. (Nasdaq:NGEN), developer of advanced diagnostic products, announced today that it has received project funding from several Canadian agencies, including the Canadian Food Inspection Agency (CFIA). The purpose of the funding and collaborative agreement is to develop diagnostic tools for the detection of natural or potential bioterror threats to livestock, such as foot and mouth disease and avian flu, employing the company’s NanoChip® platform.
“Adaptation of Recently Developed DNA Microarrays to NanoChip Microarray Technology for Detection of Agroterrorism Agents”
“Although the majority of our NanoChip® instruments are used in basic research and human clinical diagnostics applications, we have always known that the platform’s flexibility confers benefit in other markets, such as veterinary diagnostics and the monitoring of bioterror threats,” said Nanogen president and chief operating officer David Ludvigson.
Foot and mouth disease, a viral infection that devastated the beef industry in the United Kingdom in 2001, is a bioterror concern because it is easily transmissible from animal to animal. Economic losses could be enormous - the 2001 epidemic cost an estimated $12 billion, according to a study sponsored by the Wash., D.C.-based Center for Strategic and International Studies. Avian flu poses a similar threat to poultry stocks.
The NanoChip® 400 is the company’s second generation automated multiplexing platform, which uses advanced microarray technology for performing pathogen sequence detection and genotyping applications. Multiple samples with multiple targets can be applied to an open and flexible electronic microarray, the NanoChip cartridge, which may be reused until all test sites have been utilized. As the NanoChip arrays are built by users rather than containing pre-determined content, the system provides a simple, fast and cost effective means for performing molecular testing.
The project, titled “Adaptation of Recently Developed DNA Microarrays to NanoChip Microarray Technology for Detection of Agroterrorism Agents” was approved by Defence Research and Development Canada through the CRTI Program (CBRNE [Chemical, Biological, Radiological, and Nuclear] Research and Technology Initiative (CRTI). Financial terms were not disclosed. Additional collaborators include the CFIA’s laboratory in Lethbridge, Alberta and the National Center for Foreign Animal Diseases located in Winnipeg, Manitoba.
About Nanogen, Inc.
Nanogen's advanced technologies provide researchers, clinicians and physicians worldwide with improved methods and tools to predict, diagnose, and ultimately help treat disease. The company's products include real-time PCR reagents, the NanoChip® electronic microarray platform and a line of rapid diagnostic tests. Nanogen's ten years of pioneering research involving nanotechnology holds the promise of miniaturization and continues to be supported for its potential for diagnostic and biodefense applications. For additional information please visit Nanogen's website at www.nanogen.com.
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether patents owned or licensed by Nanogen will be developed into products, whether the patents owned by Nanogen offer any protection against competitors with competing technologies, whether products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in Nanogen’s Form 10-K or Form 10-Q most recently filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Nanogen disclaims any intent or obligation to update these forward-looking statements.